Skip to content

Rhythm Pharmaceuticals

US · RYTM #1874 by market cap Listed 2017
88.45 -2.32 -2.56%
Live - 5344 symbols - heartbeat 407s ago · 2026-10-07 20:00
After-hours 88.45 0.00%
Overnight 88.34 -0.12%
Market cap
6.09B
P/B
59.12
EPS
-3.11
Reader sentiment Are you bullish or bearish on RYTM?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 60.35 Expensive vs history 76th percentile
5-year average 27.48 · #497 of 514 in Biotechnology
P/E ratio -28.94 Cheap vs history 21st percentile
5-year average -15.02 · forward -38.35
P/S ratio 25.91 Cheap vs history 3rd percentile
5-year average 93.30 · forward 15.21 · #223 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Rhythm Pharmaceuticals (RYTM) 6.09B -28.35 59.12 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value127.02 Economic moatNone UncertaintyVery High

Trading 43.6% below Morningstar's fair value estimate.

Fair value

Rhythm Pharmaceuticals Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 27% discount to our quantitative fair value estimate of $127.02 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet increases our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -10.8, which lies in the bottom 10% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 3.8%, a core component of profitability, ranks in the bottom 10% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-07 20:00:08 · For reference only, not investment advice and not tailored to your situation.